Angiotensin II, oxidative stress and stem cell therapy: A matter of delicacy

Clinical Science

Volumn 128, Issue 11, 2015, Pages 749-750

  Roks, Anton J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute kidney injury; Bone marrow; Renin angiotensin system

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; LOSARTAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN;

CARDIOVASCULAR DISEASE; DONOR; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY INJURY; MITOCHONDRIAL RESPIRATION; NONHUMAN; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; REGENERATIVE MEDICINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STEM CELL TRANSPLANTATION; VASCULAR DISEASE; ACUTE KIDNEY FAILURE; ANIMAL; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ACUTE KIDNEY INJURY; ANIMALS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84929505338     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20150082     Document Type: Note

References (10)

1. Strauer, B.E. and Steinhoff, G. (2011) 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. J. Am. Coll. Cardiol. 58, 1095-1104
2. Fleig, S.V. and Humphreys, B.D. (2014) Rationale of mesenchymal stem cell therapy in kidney injury. Nephron Clin. Pract. 127, 75-80
3. Durik, M., Seva Pessoa, B. and Roks, A.J. (2012) The renin-angiotensin system, bone marrow and progenitor cells. Clin. Sci. 123, 205-223
4. Kankuri, E., Mervaala, E.E., Storvik, M., Ahola, A.M.J., Levijoki, J., Muller, D.N., Finckenberg, P. and Mervaala, E.M. (2015) Exacerbation of acute kidney injury by bone marrow stromal cells from rats with persistent renin-angiotensin system activation. Clin. Sci.
5. Endtmann, C., Ebrahimian, T., Czech, T., Arfa, O., Laufs, U., Fritz, M., Wassmann, K., Werner, N., Petoumenos, V., Nickenig, G. and Wassmann, S. (2011) Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension 58, 394-403
6. Roks, A.J. (2011) Angiotensin II deteriorates endothelial progenitor cells: good intentions with bad consequences. Hypertension 58, 356-358
7. Seva Pessoa, B., van der Lubbe, N., Verdonk, K., Roks, A.J., Hoorn, E.J. and Danser, A.H. (2013) Key developments in renin-angiotensin-aldosterone system inhibition. Nat. Rev. Nephrol. 9, 26-36
8. Van Liefde, I. and Vauquelin, G. (2009) Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol. Cell. Endocrinol. 302, 237-243
9. Rodgers, K.E. and Dizerega, G.S. (2013) Contribution of the local RAS to hematopoietic function: a novel therapeutic target. Front. Endocrinol. (Lausanne) 4, 157
10. Chang, K.H., Nayak, R.C., Roy, S., Perumbeti, A., Wellendorf, A.M., Bezold, K.Y., Pirman, M., Hill, S.E., Starnes, J., Loberg, A. et al. (2015) Vasculopathy-associated hyperangiotensinemia mobilizes haematopoietic stem cells/progenitors through endothelial AT2R and cytoskeletal dysregulation. Nat. Commun. 6, 5914